Novel Rinse to Treat in Oral Candidiasis in Cancer Patients

NCT ID: NCT00612963

Last Updated: 2010-03-08

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 23 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2007-04-30
• Study Completion Date: 2009-05-31

Brief Summary

The purpose of the study is to evaluate the efficacy of Iocide oral rinse as a treatment for Oral Candidiasis in any patient including but not limited to patients receiving radiation therapy or who have previously received radiation therapy for head and neck cancer, or patients positive for HIV/AIDS or are transplant patients.

Detailed Description

A four-week study has been designed as an assessment of the clinical cure and mycological eradication of oral Candida isolates in 40 cancer patients referred by radiation oncologists during the course of his/her treatment. An estimated 35 patients will be evaluable at the end of the study. Candida infection is defined as positive clinical signs (white plaques) with positive potassium hydroxide (KOH) preparation and positive cultures. Colonization is defined as a positive culture without signs of clinical infection.

Conditions

Candidiasis, Oral; Thrush; Candidiasis

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: PROSPECTIVE

Interventions

Frio Oral Rinse

Prescription Mouth Rinse

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Males or non-pregnant females currently receiving or post radiation therapy for head and neck cancer;
• 18 years of age;
• With signs and symptoms of oral candidiasis as determined by investigator(s);
• Females using an effective contraception method during study.
• Patients must be able and willing to comply with study requirements, and have full understanding of all elements of, and signature and dating of, informed consent prior to initiation of protocol specified procedures.
• Participating female subjects must agree to use adequate contraceptive measures during the trial. Before entering the study, women of childbearing age will be tested for pregnancy with a urine pregnancy test.

Exclusion Criteria

• History, or current evidence, of any significant acute or chronic medical or psychiatric condition that would render examination difficult or invalid or prevent the subject from active study participation;
• Inability to use an oral rinse;
• Use of concomitant medication that, in the opinion of the Study Director, might interfere with the outcome of the study (e.g. anabolic steroids or excessive corticosteroids, large doses of aspirin (no more than one 325 mg tablet per day), phenytoin, lithium, coumadin or Iodine containing preparations [use of iodized table salt is acceptable]). Steroids, therapeutic doses of non-steroidal anti-inflammatory agents, estrogen therapy agents and oral contraceptives are OK to use as long as the baseline dose remains steady through the end of the study;
• Use of antifungal medication in the last 30 days, purported sensitivity or allergy to iodine;
• Pregnant or nursing patients as the effect of Iocide in the fetus or infant are not established;
• History thyroid disease.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institute of Dental and Craniofacial Research (NIDCR)

NIH

Sponsor Role: collaborator

University of Texas

OTHER

Sponsor Role: collaborator

Biomedical Development Corporation

INDUSTRY

Sponsor Role: lead

Responsible Party

UTHSCSA

Principal Investigators

Spencer W. Redding, DDS

Role: PRINCIPAL_INVESTIGATOR

The University of Texas Health Science Center at San Antonio

Locations

University of Missouri at Kansas City, School of Dentistry

Kansas City, Missouri, United States

Cancer Therapy and Researh Center

San Antonio, Texas, United States

Countries

United States

Other Identifiers

5R44DE017301-03

Identifier Type: NIH

Identifier Source: secondary_id

View Link

HSC20070023H

Identifier Type: -

Identifier Source: org_study_id